TMBR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Nov 2023 @ 15:59):

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases...

Stats
Today's Volume	130 464
Average Volume	107 900
Market Cap	1.18M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.174
ATR14	$0.215 (2 128.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-20	Koconis John	Buy	70 385	Common Stock, par value $0.001 per share
2023-08-20	Mendelsohn Alan	Buy	35 193	Common Stock, par value $0.001 per share
2023-08-20	Lucchese Joseph	Buy	35 193	Common Stock, par value $0.001
2023-04-15	Koconis John	Buy	45 010	Stock Option (right to buy)
2023-04-15	Gaal Lubor	Buy	4 100	Common Stock, par value $0.001 per share

INSIDER POWER
100.00
Last 85 transactions
Buy: 16 585 051 \| Sell: 6 873 671

Volume Correlation

Long: 0.06 (neutral)

Short: -0.33 (neutral)

Signal:(23.664) Neutral

Timber Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Timber Pharmaceuticals Correlation - Currency/Commodity

0.25
( neutral )

0.15
( neutral )

0.09
( neutral )

-0.45
( neutral )

0.69
( moderate )

-0.65
( moderate negative )

Timber Pharmaceuticals Financials

Annual	2022
Revenue:	$83 177.00
Gross Profit:	$-13.22M (-15 892.35 %)
EPS:	$-9.19

Q2	2023
Revenue:	$0
Gross Profit:	$-2.47M (0.00 %)
EPS:	$-1.320

Q1	2023
Revenue:	$0
Gross Profit:	$-2.37M (0.00 %)
EPS:	$-1.360

Q4	2022
Revenue:	$83 177.00
Gross Profit:	$-2.02M (-2 425.90 %)
EPS:	$-1.720

Financial Reports:

No articles found.

Timber Pharmaceuticals

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.